Novacyt S.A.

As of December 31, 2024, Novacyt S.A. carries a market capitalization of 3.50B, placing it among publicly traded companies globally. Its enterprise value stands at 1.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novacyt S.A.'s next confirmed earnings release is scheduled for April 29, 2027.

As of December 31, 2024, Novacyt S.A. has 70.63M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Novacyt S.A. maintains a current ratio of 6.33, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 23, 2026, Novacyt S.A.'s stock has declined approximately 6.37% over the past 52 weeks. The 50-day moving average sits at 42.14, while the 200-day moving average is 38.15.

As of December 31, 2024, Novacyt S.A. holds 3.05B in cash and equivalents against 1.19B in total debt, resulting in a net debt position of -3.05B. Total book value stands at 4.79B, with working capital of 3.32B providing operational flexibility.